Also towards that direction, a research project is ongoing, aiming to create a novel point-of-care device that will be able to measure multiple saliva biomarkers (NT-proBNP, cortisol and possibly also TNF–α and IL-10) in HF patients and non-HF patients with risk factors such as obesity or hypertension. This evidence concerns the gene NPPB and hypertensive disorder.